Liver Diseases  >>  deleobuvir (BI 207127)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
deleobuvir (BI 207127) / Boehringer Ingelheim
NCT01728324 / 2012-003535-27: Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Checkmark AASLD 2014: HCVerso 2
Oct 2014 - Oct 2014: AASLD 2014: HCVerso 2
Completed
3
496
US, Canada, Europe, RoW
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Boehringer Ingelheim
Hepatitis C, Chronic
02/14
01/15
NCT01858961 / 2012-004544-30: Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Withdrawn
3
0
Europe, RoW
BI 201335, ribavirin, BI 207127, Telaprevir, Pegylated Interferon
Boehringer Ingelheim
Hepatitis C, Chronic
07/16
07/16

Download Options